{"filing":{"accession_number":"0001171843-26-004068","cik":"0001738021","ticker":"CMPX","company_name":"Compass Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"f8k_061126.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1738021/000117184326004068/f8k_061126.htm"},"events":[{"id":5326,"run_id":4664,"accession_number":"0001171843-26-004068","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of Compass Therapeutics' Annual Meeting of Stockholders held on June 10, 2026. The filing presents voting results for four proposals: election of two Class III directors (Schuetz and Lindahl), ratification of CohnReznick LLP as independent auditor, advisory vote on named executive officer compensation, and advisory vote frequency on compensation. The detailed vote tallies (For/Against/Withheld/Broker Non-votes) for each proposal are the core content of this 8-K section.","company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6218,"accession_number":"0001171843-26-004068","item_number":"5.07","item_title":"Submission","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Compass Therapeutics' Annual Meeting of Stockholders held on June 10, 2026. The filing presents voting results for four proposals: election of two Class III directors (Schuetz and Lindahl), ratification of CohnReznick LLP as independent auditor, advisory vote on named executive officer compensation, and advisory vote frequency on compensation. The detailed vote tallies (For/Against/Withheld/Broker Non-votes) for each proposal are the core content of this 8-K section.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:02:05.876925+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6218,"accession_number":"0001171843-26-004068","item_number":"5.07","item_title":"Submission","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Compass Therapeutics' Annual Meeting of Stockholders held on June 10, 2026. The filing presents voting results for four proposals: election of two Class III directors (Schuetz and Lindahl), ratification of CohnReznick LLP as independent auditor, advisory vote on named executive officer compensation, and advisory vote frequency on compensation. The detailed vote tallies (For/Against/Withheld/Broker Non-votes) for each proposal are the core content of this 8-K section.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:02:05.876925+00:00","company_name":"Compass Therapeutics, Inc.","ticker":"CMPX","filing_date":"2026-06-11"}]}